We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Cancer DNA in Blood Helps Personalize Liver Cancer Treatment

By LabMedica International staff writers
Posted on 15 Nov 2015
Print article
Image: Schematic diagram of circulating tumor DNA (ctDNA), a small piece of DNA released from dying cancer cells into the blood (Photo courtesy of Jonathan Bailey).
Image: Schematic diagram of circulating tumor DNA (ctDNA), a small piece of DNA released from dying cancer cells into the blood (Photo courtesy of Jonathan Bailey).
Liver cancer tumor specimens are difficult and sometimes dangerous to obtain, and noninvasive methods are required to assess cancer progression and characterize underlying genomic features.

The detection of DNA released by damaged cancer cells, called circulating tumor DNA (ctDNA), in serum before surgery could predict the recurrence of cancer and its metastatic spread through the body in patients with an advanced form of the most common type of liver cancer.

Scientists at the Hiroshima University (Japan) and their colleagues analyzed 46 patients with hepatocellular carcinoma who underwent hepatectomy or liver transplantation and for whom whole-genome sequencing data was available. They designed personalized assays targeting somatic rearrangements of each tumor to quantify serum ctDNA. Exome sequencing was performed using cell-free DNA paired primary tumor tissue DNA from a patient with recurrent liver cancer after transcatheter arterial chemoembolization (TACE).

The team used a chemiluminescent immunoassay (Fujirebio; Tokyo, Japan) and chemiluminescent enzyme immunoassay (Abbott Laboratories, Abbott Park, IL, USA) to analyze α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), respectively. Thresholds for AFP and DCP abnormalities were defined as 10 ng/mL and 30 mAU/mL, respectively. Cell-free DNA was extracted from 100 μL of preoperative serum by the SMI-TEST (Genome Science Laboratories, Tokyo, Japan). Real-time polymerase chain reaction (PCR) analysis was performed on samples that tested positive in the detection assay and for which serial serum samples were available. PCR was performed using the Mx300P System (Applied Biosystems, Foster City, CA, USA).

The investigators were able to identify 25 common mutations in samples of cell-free DNA, which includes DNA from both normal cells and cancer cells, and DNA from tumors themselves. Furthermore, 83% of mutations identified in the tumor tissues could be detected in the cell-free DNA. They found ctDNA in seven patients and they say that ctDNA has the potential to be a noninvasive way of studying the genetic rearrangements that a cancer has undergone. This information could help doctors provide targeted therapy specific to a patient's cancer. They also demonstrated that the level of serum ctDNA reflected the treatment effect and the progression of hepatocellular carcinoma (HCC). The study was published in the September 2015 issue of the journal Cellular and Molecular Gastroenterology and Hepatology.

Related Links:

Hiroshima University 
Fujirebio 
Abbott Laboratories 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.